Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies

International Journal of Geriatric Psychiatry

Volumn 28, Issue 7, 2013, Pages 738-744

  Brunnström, Hans ^a   Hansson, Oskar ^a   Zetterberg, Henrik ^b   Londos, Elisabet ^a   Englund, Elisabet ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Alzheimer's disease; autopsy; biomarkers; cerebrospinal fluid; dementia; Lewy body disease; neuropathology

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PROTEIN; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; DIFFUSE LEWY BODY DISEASE; FEMALE; FOLLOW UP; HUMAN; IN VIVO STUDY; MALE; MINI MENTAL STATE EXAMINATION; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; SENILE PLAQUE; TIME OF DEATH; VASCULAR AMYLOIDOSIS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID; BIOLOGICAL MARKERS; CEREBRAL AMYLOID ANGIOPATHY; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; PLAQUE, AMYLOID; REGRESSION ANALYSIS; TAU PROTEINS;

EID: 84878765032     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.3881     Document Type: Article

References (34)

1. Andreasen N, Hesse C, Davidsson P, et al,. 1999. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 56: 673-680.
2. Blennow K, Wallin A, Agren H, et al,. 1995. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26: 231-245.
3. Blennow K, Hampel H, Weiner M, Zetterberg H,. 2010. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6: 131-144.
4. Boström F, Hansson O, Blennow K, et al,. 2009. Cerebrospinal fluid total tau is associated with shorter survival in dementia with Lewy bodies. Dement Geriatr Cogn Disord 28: 314-319.
5. Braak H, Braak E,. 1991. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82: 239-259.
6. Braak H, Del Tredici K, Rüb U, et al,. 2003. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197-211.
7. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K,. 2006. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112: 389-404.
8. Brunnström H, Englund E,. 2011. Comparison of four neuropathological scales for Alzheimer's disease. Clin Neuropathol 30: 56-69.
9. Brunnström H, Rawshani N, Zetterberg H, et al,. 2010. Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses. Alzheimers Dement 6: 104-109.
10. Brunnström H, Lindberg E, Englund E,. 2012. Staging of Lewy-related pathology in dementia. Clin Neuropathol 31: 216-223.
11. Buerger K, Ewers M, Pirttilä T, et al,. 2006. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129: 3035-3041.
12. Clark CM, Xie S, Chittams J, et al,. 2003. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 60: 1696-1702.
13. Engelborghs S, Maertens K, Vloeberghs E, et al,. 2006. Neuropsychological and behavioural correlates of CSF biomarkers in dementia. Neurochem Int 48: 286-295.
14. Engelborghs S, Sleegers K, Cras P, et al,. 2007. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. Brain 130: 2320-2326.
15. Engelborghs S, De Vreese K, Van de Casteele T, et al,. 2008. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 29: 1143-1159.
16. Folstein MF, Folstein SE, McHugh PR,. 1975. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
17. Gómez-Tortosa E, Gonzalo I, Fanjul S, et al,. 2003. Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease. Arch Neurol 60: 1218-1222.
18. van Harten AC, Kester MI, Visser PJ, et al,. 2011. Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin Chem Lab Med 49: 353-366.
19. Jellinger KA,. 2006. Clinicopathological analysis of dementia disorders in the elderly-an update. J Alzheimers Dis 9 (Suppl): 61-70.
20. Jellinger KA, Wenning GK, Seppi K,. 2007. Predictors of survival in dementia with Lewy bodies and Parkinson dementia. Neurodegener Dis 4: 428-430.
21. McKeith IG, Dickson DW, Lowe J, et al,.; Consortium on DLB. 2005. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65: 1863-1872.
22. Mirra SS, Heyman A, McKeel D, et al,. 1991. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41: 479-486.
23. Mollenhauer B, Bibl M, Wiltfang J, et al,. 2006. Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies. Clin Chem Lab Med 44: 192-195.
24. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al,. 2011. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with Parkinsonism: a cohort study. Lancet Neurol 10: 230-240. Erratum in: 2011. Lancet Neurol 10: 297.
25. Olichney JM, Galasko D, Salmon DP, et al,. 1998. Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology 51: 351-357.
26. Sjögren M, Vanderstichele H, Agren H, et al,. 2001. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 47: 1776-1781.
27. Strozyk D, Blennow K, White LR, Launer LJ,. 2003. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60: 652-656.
28. Tapiola T, Alafuzoff I, Herukka SK, et al,. 2009. Cerebrospinal fluid beta-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66: 382-389.
29. Tschampa HJ, Schulz-Schaeffer W, Wiltfang J, et al,. 2001. Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 56: 576.
30. Vanderstichele H, De Vreese K, Blennow K, et al,. 2006. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med 44: 1472-1480.
31. Vanmechelen E, Vanderstichele H, Davidsson P, et al,. 2000. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285: 49-52.
32. Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O,. 2010. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 74: 1531-1537.
33. Williams MM, Xiong C, Morris JC, Galvin JE,. 2006. Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease. Neurology 67: 1935-1941.
34. Zaccai J, McCracken C, Brayne C,. 2005. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 34: 561-566.